{
    "clinical_study": {
        "@rank": "87412", 
        "arm_group": {
            "arm_group_label": "Pemetrexed and Temozolomide", 
            "arm_group_type": "Experimental", 
            "description": "Patients with relapsed PCNSL patients were treated with high-dose pemetrexed (900mg/m2) and temozolomide (200mg/m\u00b2 day 1-5, 28 day cycle)."
        }, 
        "brief_summary": {
            "textblock": "In this trial, we will treat relapsed PCNSL with temozolomide, pemetrexed. Our objective was\n      to assess our treatment strategies' availability based on response rates, progression-free\n      survival (PFS), median PFS, and toxicity."
        }, 
        "brief_title": "Pemetrexed and Temozolomide in Treating Patients With Relapsed Primary Central Nervous System Lymphoma \uff08PCNSL\uff09", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Central Nervous System Tumors", 
        "condition_browse": {
            "mesh_term": [
                "Nervous System Neoplasms", 
                "Central Nervous System Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "The best reported outcomes of PCNSL treatment are high-dose methotrexate-based chemotherapy\n      combined with whole-brain radiation therapy (WBRT). Despite aggressive therapy, however,\n      nearly 50% of patients will relapse within 24 months of diagnosis. Furthermore, the\n      application of high-dose methotrexate-based regimen is complex, needing be hydrated,\n      alkalified and detoxified, and treatment-related toxicity mortality is severe. In an attempt\n      to improve upon these poor results and reduce treatment-related side effects, we will treat\n      about 15-20 relapsed PCNSL patients who was fail in high-dose methotrexate-based\n      chemotherapy. Our objective is to assess our treatment strategies' availability based on\n      response rates, progression-free survival (PFS), median PFS, and toxicity."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically confirmed primary CNS lymphoma.\n\n          -  ECOG (Eastern Cooperative Oncology Group) Performance status of 0-1.\n\n          -  Positive cerebrospinal fluid (CSF) cytology or immunohistochemical diagnosis of CSF\n             monoclonality with or without measurable intracranial disease.\n\n          -  Measurable (greater than 1 cm in diameter) tumor by CT scan or MRI.\n\n          -  Progressed during first-line chemotherapy and/or radiotherapy OR relapsed after\n             initial successful treatment.\n\n          -  No systemic lymphoma by CT scan of the chest, abdomen, and pelvis with contrast.\n\n          -  No leptomeningeal lymphoma by lumbar puncture for CNS cytology/flow cytometry.\n\n          -  No ocular lymphoma by slit lamp examination.\n\n          -  Must have adequate organ function as defined by the protocol: Adequate renal\n             function: serum creatinine \u2264 1.5 mg/dl and/or calculated creatinine clearance \u2265 60\n             ml/min; Adequate hepatic function: bilirubin level \u2264 1.5 x ULN, ASAT & ALST \u2264 1.5 x\n             ULN.Adequate bone marrow reserves: neutrophil (ANC) count \u2265 1500 /mm^3, platelet\n             count \u2265 100,000 /mm^3, hemoglobin \u2265 9 g/dl.\n\n          -  Age >/= 18 and </= 75 years.\n\n          -  Signed written informed consent prior to study entry.\n\n        Exclusion Criteria:\n\n          -  Patients with human immunodeficiency virus seropositivity and systemic lymphoma\n             manifestation.\n\n          -  Serious uncontrolled concurrent illness.\n\n          -  Previous brain radiotherapy, systemic chemotherapy.\n\n          -  Concurrent chronic systemic immune therapy, targeted therapy not indicated in this\n             study protocol.\n\n          -  Any evidence of prior exposure to Hepatitis B virus.\n\n          -  Unable to comprehend the study requirements or who are not likely to comply with the\n             study parameters.\n\n          -  Pregnant (confirmed by serum or urine \u03b2-HCG) or lactating."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01985451", 
            "org_study_id": "ShandongCHI002", 
            "secondary_id": "ShandongCHI"
        }, 
        "intervention": [
            {
                "arm_group_label": "Pemetrexed and Temozolomide", 
                "description": "Patients with relapsed PCNSL patients were treated with high-dose pemetrexed (900mg/m\u00b2).", 
                "intervention_name": "Pemetrexe", 
                "intervention_type": "Drug", 
                "other_name": "Alimta"
            }, 
            {
                "arm_group_label": "Pemetrexed and Temozolomide", 
                "description": "Patients with relapsed PCNSL patients were treated with temozolomide (200mg/m\u00b2 day 1-5,28).", 
                "intervention_name": "Temozolomide", 
                "intervention_type": "Drug", 
                "other_name": "Temodal"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Temozolomide", 
                "Dacarbazine", 
                "Pemetrexed"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Lymphoma", 
        "lastchanged_date": "November 8, 2013", 
        "number_of_arms": "1", 
        "official_title": "Phase II Trial of Pemetrexed and Temozolomide in Treating Patients With Relapsed PCNSL", 
        "overall_official": {
            "affiliation": "Study Director", 
            "last_name": "Yong Wang, master", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "China: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Contrast MRI was performed to assess treatment response at 3-month interval for 2 years and thereafter every 6 months for next 3-5 years and then annually. The treatment response was reassessed according to International PCNSL Collaborative Group' criteria[1].\n[1] Abrey LE, Batchelor TT, Ferreri AJ, Gospodarowicz M, Pulczynski EJ, Zucca E, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. International Primary CNS Lymphoma Collaborative Group. J Clin Oncol 2005;23:5034-43.", 
            "measure": "complete response (CR)", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01985451"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Shandong Cancer Hospital and Institute", 
            "investigator_full_name": "Rongjie Tao", 
            "investigator_title": "Neurosurgery", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "results_reference": [
            {
                "PMID": "22179954", 
                "citation": "Raizer JJ, Rademaker A, Evens AM, Rice L, Schwartz M, Chandler JP, Getch CC, Tellez C, Grimm SA. Pemetrexed in the treatment of relapsed/refractory primary central nervous system lymphoma. Cancer. 2012 Aug 1;118(15):3743-8. doi: 10.1002/cncr.26709. Epub 2011 Dec 16."
            }, 
            {
                "PMID": "23828279", 
                "citation": "Zhang JP, Lee EQ, Nayak L, Doherty L, Kesari S, Muzikansky A, Norden AD, Chen H, Wen PY, Drappatz J. Retrospective study of pemetrexed as salvage therapy for central nervous system lymphoma. J Neurooncol. 2013 Oct;115(1):71-7. doi: 10.1007/s11060-013-1196-1. Epub 2013 Jul 5."
            }, 
            {
                "PMID": "24178621", 
                "citation": "Leshchenko V, Kuo PY, Jiang Z, Thirukonda VK, Parekh S. Integrative genomic analysis of Temozolomide resistance in Diffuse Large B Cell Lymphoma. Clin Cancer Res. 2013 Oct 31. [Epub ahead of print]"
            }
        ], 
        "secondary_outcome": [
            {
                "description": "Contrast MRI was performed to assess treatment response. PFS was defined as the time from initial diagnosis until disease progression. PFS and median PFS were analyzed using the Kaplan-Meier product limit curve.", 
                "measure": "Failure-free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Toxicity was graded according to the Word Health Organization (WHO) classification.\nFor example:hematotoxicity,nausea,fatigue, abnormal liver function, alopecia, peripheral nerve damage, and constipation et al.", 
                "measure": "Toxicity", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "The disease control rate,This is the equivalent to Overall response rate, was (CR+ PR+SD).CR:complete respons; PR:partial response; SD:stable disease.", 
                "measure": "Overall response rate (ORR)", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }
        ], 
        "source": "Shandong Cancer Hospital and Institute", 
        "sponsors": {
            "collaborator": {
                "agency": "National Natural Science Foundation of China", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Rongjie Tao", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}